Results 11 to 20 of about 20,950 (257)

Bimekizumab versus Secukinumab in Plaque Psoriasis.

New England Journal of Medicine, 2021
BACKGROUND Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients ...
K. Reich, R. Warren, M. Lebwohl, M. Gooderham, B. Strober, R. Langley, C. Paul, D. de Cuyper, V. Vanvoorden, C. Madden, C. Cioffi, L. Peterson, A. Blauvelt   +12 more
semanticscholar   +1 more source

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To evaluate the efficacy and safety of Secukinumab versus Adalimumab in the treatment of the moderate to severe plaque psoriasis. Methods A total of 90 patients with moderate to severe psoriasis were randomly divided into three groups ...
Dandan HU, Peimiao ZHANG
doaj   +1 more source

Active pulmonary tuberculosis in a patient with secukinumab treatment

Radiology Case Reports, 2023
Numerous investigations have documented active tuberculosis (TB) infection following biologic treatment. One of the most secure biologic medications for infections is secukinumab.
Cao Thanh Ngoc, MD, PhD, Bui Dang Khoa, MD, Huynh Khoi Nguyen, MD, Le Bao Le, MD, Dang Vinh Hiep, MD, PhD, Nguyen Minh Duc, MD   +5 more
doaj   +1 more source

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study

Chinese Medical Journal, 2021
. Background:. There have been few real-life dose-comparing studies on the efficacy and safety of secukinumab in Chinese patients with plaque psoriasis.
Yan Zhao, Lin Cai, Xiao-Yang Liu, Heng Zhang, Jian-Zhong Zhang, Li-Shao Guo   +5 more
doaj   +1 more source

Secukinumab in active rheumatoid arthritis after anti-TNFα therapy : a randomized, double-blind placebo-controlled phase 3 study [PDF]

, 2017
Introduction: 'REASSURE' (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF ...
Aelion, Jacob, Deodhar, Atul, Genovese, Mark, Haemmerle, Sibylle, Richards, Hanno B, Tahir, Hasan, Takeuchi, Tsutomu, Van den Bosch, Filip   +7 more
core   +7 more sources

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study

ACR Open Rheumatology, 2020
Objective Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years.
Karel Pavelka, Alan J. Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Yi Wang, Brian O. Porter, Anna Stefanska, Hanno B. Richards, Susanne Rohrer, the MEASURE 3 study group   +11 more
doaj   +1 more source

Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]

, 2018
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal, Hunger, Matthias, Jugl, Steffen M., Karabis, Andreas, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Nash, Peter, Thom, Howard   +8 more
core   +2 more sources

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review

Rheumatology and Therapy, 2019
Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States.
Prashanth Sunkureddi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Peter Hur, Reeti Joshi   +5 more
doaj   +1 more source

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats, Blanco, Ricardo, Dokoupilova, Eva, FUTURE 3 study group, Kajekar, Radhika, McInnes, Iain B, Mease, Philip J, Mpofu, Shephard, Nash, Peter, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T   +11 more
core   +1 more source

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis

Rheumatology and Therapy, 2023
Introduction This study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA). Methods A total of 84 patients with oligoarticular PsA, defined as 1–4 tender joints and 1–4 swollen ...
Alexis Ogdie, Dafna D. Gladman, Laura C. Coates, Effie Pournara, Bhumik Parikh, Philip J. Mease   +5 more
doaj   +1 more source